The EAY191-N4 clinical study, A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patientswith Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers, part of the ComboMATCH precision medicine initiative, is open for women who have recurrent or persistent ovarian and endometrial with a RAS pathway mutation, including activating mutations in KRAS, NRAS, HRAS, BRAF, MEK1, and MEK2, or in activating mutations in NF1. The trial will be comparing the combination of the MEK inhibitor Selumetinib and the PARP inhibitor Olaparib to Selumetinib alone for this patient population. The study will be occurring in two different cohorts. Cohort 1 will consist of patients with ovarian cancer and Cohort 2 will include patients with endometrial cancer.
Make America Healthy Again
President Trump released an Executive Order (EO) establishing the "Make America Healthy Again (MAHA) Commission,” Feb. 13 to be led by the new Department of Health and Human Services Secretary Robert F. Kennedy Jr.
Read moreScope of Practice Bills Introduced At State Legislative Level
The American College of Radiology® (ACR®) is tracking more than 58 scope of practice bills across 22 states with more expected to be considered.
Read moreACR Others Challenge MAC Position on Minimally Invasive Arthrodesis of the Sacroiliac Joint
The American College of Radiology® (ACR®) and other medical specialty societies that use or perform interventional pain and spine procedures told three of the seven Medicare Administrative Contractors (MACs) that implementation of a new policy as written could limit access to a safe, effective and durable treatment option, potentially exacerbating healthcare disparities among Medicare patients.
Read more